^
    Back
    Association details:
    Biomarker:CHEK2 mutation
    Cancer:Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    JCO Precis Oncol
    Title:

    Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes

    Published date:
    03/02/2022
    Excerpt:
    Median progression-free survival was shorter in patients with evaluated germline pathogenic variants (10.2 months [95% CI, 5.7 to 14.7])...In this retrospective real-world study, gBRCA1/2-ATM-CHEK2 pathogenic variants were independently associated with poor outcomes in patients with advanced breast cancer treated with CDK4/6 inhibitors.
    DOI:
    10.1200/PO.21.00140